verapamil has been researched along with lovastatin in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 9 (39.13) | 29.6817 |
| 2010's | 10 (43.48) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Cvetkovic, M; Fromm, MF; Kim, RB; Leake, B; Wilkinson, GR | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Freiwald, S; Jiang, Y; Jones, JP; Kaspera, R; Katayama, J; Lee, CA; Smith, E; Totah, RA; Walker, GS | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Guo, HF; Jin, J; Li, ZR; Liu, ZY; Xie, ZS; Xue, ST; Yi, H; Zhang, L | 1 |
| Biade, S; Mazière, C; Mazière, JC; Mora, L; Santus, R | 1 |
| Abe-Dohmae, S; Arakawa, R; Inoue, K; Nishimaki-Mogami, T; Suzuki, S; Tamehiro, N; Tanaka, AR; Ueda, K; Yokoyama, S | 1 |
| Aguilar, P; Muñoz Díaz, AB | 1 |
| Elston Lafata, J; Horn, JR; Kaatz, S; Raebel, MA; Schultz, L; Simpkins, J; Smith, DH; Yood, MU | 1 |
| Chang, KS; Choi, DH; Choi, JS; Hong, SP; Koh, YY | 1 |
| Choi, DH; Choi, JS; Chung, JH | 1 |
| Kang, W; Kim, Y; Park, K | 1 |
| Ahmad, S; Ali, N; Ali, W; Rahman, SU; Ullah, A | 1 |
1 review(s) available for verapamil and lovastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for verapamil and lovastatin
| Article | Year |
|---|---|
Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin.
Topics: Administration, Oral; Adult; Area Under Curve; Asian People; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Half-Life; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Absorption; Korea; Lovastatin; Male; Verapamil; Young Adult | 2010 |
21 other study(ies) available for verapamil and lovastatin
| Article | Year |
|---|---|
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
Topics: Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Caco-2 Cells; Carrier Proteins; Genes, MDR; HeLa Cells; Histamine H1 Antagonists; Humans; LLC-PK1 Cells; Mice; Rats; Swine; Terfenadine; Tissue Distribution; Transfection; Vaccinia virus | 1999 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
Topics: 3T3 Cells; Adrenergic Uptake Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport, Active; Cell Line; Cell Separation; Cell Survival; Flow Cytometry; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Mice; Protein Binding; Reserpine; Spectrometry, Fluorescence; Substrate Specificity; Time Factors | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Topics: Amiodarone; Astemizole; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Danazol; Drug Discovery; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Methylation; Microsomes, Liver; Models, Biological; Molecular Structure; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
Topics: Animals; Benzofurans; Bone Morphogenetic Protein 2; Caco-2 Cells; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Mice; Mice, Inbred BALB C; Molecular Structure; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thiophenes; Zebrafish | 2020 |
[Potentiation of the photocytotoxic effect of photofrin II: synergistic action of verapamil and lovastatin].
Topics: Colonic Neoplasms; Dihematoporphyrin Ether; Drug Synergism; Humans; Lovastatin; Photochemotherapy; Tumor Cells, Cultured; Verapamil | 1994 |
Verapamil increases the apolipoprotein-mediated release of cellular cholesterol by induction of ABCA1 expression via Liver X receptor-independent mechanism.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Apolipoprotein A-I; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; beta-Cyclodextrins; Bucladesine; Calcium Channel Blockers; Cell Line; Cholesterol; DNA-Binding Proteins; Gene Expression Regulation; Genes, Reporter; Humans; Hydroxycholesterols; Lipoproteins; Lipoproteins, HDL; Liver X Receptors; Lovastatin; Macrophages; Mice; Nicardipine; Nifedipine; Orphan Nuclear Receptors; Phospholipids; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Stereoisomerism; Transfection; Verapamil | 2004 |
[Idiopathic membranous nephropathy associated with anti-calcineurin toxicity. Prognosis and other immunosuppressive treatments].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcineurin Inhibitors; Calcium Channel Blockers; Creatinine; Cyclosporine; Drug Therapy, Combination; Glomerulonephritis, Membranous; Humans; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Immunosuppressive Agents; Kidney Diseases; Lisinopril; Lovastatin; Male; Nephrotic Syndrome; Prednisone; Recurrence; Verapamil | 2004 |
What do medical records tell us about potentially harmful co-prescribing?
Topics: Adult; Ambulatory Care; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Digoxin; Diltiazem; Drug Interactions; Drug Utilization Review; Health Maintenance Organizations; Humans; Lovastatin; Medical Audit; Medication Errors; Office Visits; Polypharmacy; United States; Verapamil; Warfarin | 2007 |
Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin.
Topics: Administration, Oral; Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Calcium Channel Blockers; Cytochrome P-450 CYP3A; Drug Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Metabolic Detoxication, Phase I; Rats; Rats, Sprague-Dawley; Substrate Specificity; Verapamil | 2009 |
Effect of fluvastatin, lovastatin, nifedipine and verapamil on the systemic exposure of nateglinide in rabbits.
Topics: Animals; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Calcium Channel Blockers; Cyclohexanes; Cytochrome P-450 CYP2C9; Cytochrome P450 Family 2; Diabetes Mellitus, Type 2; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Indoles; Lovastatin; Male; Nateglinide; Nifedipine; Phenylalanine; Rabbits; Steroid 21-Hydroxylase; Verapamil | 2010 |
Pitavastatin and Lovastatin Exhibit Calcium Channel Blocking Activity Which Potentiate Vasorelaxant Effects of Amlodipine: A New Futuristic Dimension in Statin's Pleiotropy.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Calcium Channels; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Norepinephrine; Rabbits; Vasodilator Agents; Verapamil | 2023 |